edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Oryzon Genomics has announced that the first patient has been dosed in its new Phase Ib trial in myelodysplastic syndrome (MDS), led by the Medical College of Wisconsin. This study (NCT06502145) aims to evaluate the safety, tolerability and recommended Phase II dose of iadademstat when administered in combination with the standard-of-care, azacitidine, in adults with MDS.
Industrials | Comment
TMT | Comment
Industrials | Comment
Industrials | Comment
Get access to the very latest content matched to your personal investment style.